Amicus Therapeutics Enters Material Definitive Agreement
Ticker: FOLD · Form: 8-K · Filed: May 1, 2025 · CIK: 1178879
| Field | Detail |
|---|---|
| Company | Amicus Therapeutics, Inc. (FOLD) |
| Form Type | 8-K |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, disclosure
TL;DR
Amicus Therapeutics signed a big deal on 4/28/25. Details to follow.
AI Summary
On April 28, 2025, Amicus Therapeutics, Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Princeton, New Jersey.
Why It Matters
This filing indicates a significant new contract or partnership for Amicus Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the nature and impact of which are not yet fully detailed in this initial filing.
Key Players & Entities
- Amicus Therapeutics, Inc. (company) — Registrant
- April 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Princeton, New Jersey (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Amicus Therapeutics?
The filing states that Amicus Therapeutics, Inc. entered into a material definitive agreement on April 28, 2025, but the specific details of this agreement are not provided in this initial 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 28, 2025.
Where is Amicus Therapeutics, Inc. headquartered?
Amicus Therapeutics, Inc.'s principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.
What is the state of incorporation for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. is incorporated in Delaware.
What other information is included in this 8-K filing besides the material definitive agreement?
This 8-K filing also includes Regulation FD disclosures and financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding AMICUS THERAPEUTICS, INC. (FOLD).